当前位置:主页 > 医学论文 > 妇产科论文 >

甲氨蝶呤治疗异位妊娠的疗效及其影响因素分析

发布时间:2018-05-16 06:18

  本文选题:甲氨蝶呤 + 给药方案 ; 参考:《中国临床药理学杂志》2015年05期


【摘要】:目的分析甲氨蝶呤(MTX)治疗异位妊娠(EP)的临床疗效,并建立其特征指标治疗前血清人绒毛膜促性腺激素(h CG)的临界值。方法入选2010年4月至2012年3月福建省妇幼保健院用MTX治疗的异位妊娠患者150例为研究对象,分为2组。试验组(n=78)用1 mg·kg-1MTX分3次间隔48 h肌内注射;对照组(n=72)用1 mg·kg-1MTX,单次肌内注射;2组均根据血清h CG下降幅度,必要时可再给MTX。比较MTX不同给药方案的临床疗效及不良反应发生率,并分析血清h CG等因素对MTX近期疗效的影响。结果 2组的临床疗效比较差异无统计学意义(P0.05)。试验组不良反应发生率低于对照组,差异有统计学意义(P0.05)。试验组治疗前血清h CG最佳工作点为1495.49 m IU·m L-1。结论 MTX多次给药方案的临床疗效与单剂方案相当,但不良反应发生率较低;治疗前血清h CG≤1500 m IU·m L-1可选用该方案。
[Abstract]:Objective to analyze the clinical efficacy of methotrexate (MTX) in the treatment of ectopic pregnancy (EPV) and to establish the critical value of serum human chorionic gonadotropin (hCG) before treatment. Methods from April 2010 to March 2012, 150 patients with ectopic pregnancy treated with MTX in Fujian Maternal and Child Health Care Hospital were selected as study subjects, and divided into two groups. In the test group, 1 mg kg-1MTX was injected intramuscularly at intervals of 48 h, while the control group was given 1 mg kg-1 MTX. The two groups were treated with a single intramuscular injection of 1 mg kg-1 MTX. To compare the clinical efficacy and adverse reaction rate of different MTX regimen, and to analyze the influence of serum hCG and other factors on the short-term efficacy of MTX. Results there was no significant difference in clinical efficacy between the two groups (P 0.05). The incidence of adverse reactions in the test group was lower than that in the control group, and the difference was statistically significant (P 0.05). The optimal working point of serum hCG before treatment was 1495.49 m IU m L -1 in the experimental group. Conclusion the clinical efficacy of MTX regimen is similar to that of single dose regimen, but the incidence of adverse reactions is low, and the serum hCG 鈮,

本文编号:1895789

资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/fuchankeerkelunwen/1895789.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户5c71a***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com